Role of DAF in Protecting against T-Cell Autoreactivity that Leads to Experimental Autoimmune Uveitis

Open Access
Publisher Website
Google Scholar
Abstract
Purpose. To investigate the role of decay-accelerating factor (DAF), a cell surface complement regulator that recently has been linked to T-cell responses and autoimmunity in the pathogenesis of experimental autoimmune uveitis (EAU). methods. EAU was induced in wild-type (WT) and Daf1 −/− mice, and their disease severities, IRBP specific Th1/Th17 responses, and cytokine expression profiles were compared. In a test of the efficacy of treatment with soluble mouse DAF protein, EAU was induced in disease-susceptible B10.RIII mice, and they were treated with 0.5 mg soluble DAF protein or equal volume of PBS IP every other day. Retinal histology and IRBP-specific T-cell responses were compared after 14 days. results. Both EAU incidence and histopathology scores were significantly greater in Daf1 −/− mice. There was a >10-fold greater mononuclear cell influx into the retina together with severe vasculitic lesions, retinal folding, and photoreceptor cell layer destruction. There were 5- to 7-fold greater Th1 and 3- to 4-fold greater Th17 responses against IRBP in Daf1 −/− mice with EAU, and they expressed significantly elevated levels of GM-CSF, IL-2, IL-3, and IFN-γ. WT B10.RIII mice that received soluble DAF protein treatments exhibited decreased IRBP-specific Th1/Th17 responses and were protected from retinal injury compared with the mice that received PBS treatments. conclusions. DAF significantly influences IRBP-specific Th1 and Th17 responses and disease severity in EAU. Systemic upregulation of DAF levels could be used to suppress retinal antigen(s)–specific autoimmunity to treat autoimmune posterior uveitis.

This publication has 38 references indexed in Scilit: